复发难治性多发性骨髓瘤的免疫靶向治疗及存在的问题

Immune,targeted therapy and related issues of relapsed/refractory multiple myeloma

多发性骨髓瘤以及复发难治性多发性骨髓瘤的新型免疫靶向治疗药物主要包括免疫调节剂、蛋白酶体抑制剂、单克隆抗体、免疫检查点抑制剂、组蛋白去乙酰化酶及嵌合抗原受体。尽管自体造血干细胞移植及新药的应用改善了患者预后,但仍需更有效的治疗手段和策略应对治疗中出现的不良反应及复发情况。

The new immune and targeted therapy medicines of multiple myeloma and recurrence of refractory multiple myeloma mainly include immunomodulatory drugs,proteasome inhibitors,monoclonal antibody,immune monitoring point inhibitors,histone deacetylase and chimeric antigen receptor.Although the emergence of new drugs and the application of autologous hematopoietic stem cell transplantation have significantly improved the prognosis of patients,more effective treatment methods and treatment strategies are still required to deal with the adverse reactions and the condition of recurrence during treatment.